Source. Diagnosis established upon demonstration of the major criterion combined with at least one minor criterion (and absence of any other disease better accounting for the problems).
Major Criterion:
- Constellation of clinical complaints attributable to pathologically increased MC activity (MC mediator release syndrome)
Minor Criteria:
-
Multifocal or disseminated infiltrates of MCs in marrow and/or extracutaneous organ(s) (e.g., gastrointestinal or genitourinary tract; >19 MCs/high power field)
-
Abnormal spindle-shaped morphology in >25% of MCs in marrow or other extracutaneous organ(S)
-
Abnormal MC expression of CD2 and/or CD25 (i.e., co-expression of CD117/CD25 or CD117/CD2)
-
MC genetic changes (e.g., activating KIT codon 419, 509 or 560 mutations) shown to increase MC activity
-
Evidence (typically from body fluids such as whole blood, serum, plasma, or urine) of above-normal levels of MC mediators including: tryptase, histamine or its metabolites (e.g., N-methylhistamine), heparin, chromogranin A (note potential confounders of cardiac or renal failure, neuroendocrine tumors, recent proton pump inhibitor use, or chronic atrophic gastritis), other relatively MC-specific mediators (e.g., ecosanoids including prostaglandin (PG) D2, its metabolite 11-B-PGF2a, or leukotriene E4)
-
Symptomatic response to inhibitors of MC activation or MC mediator production or action.